SUPIMA
6.10.2020 15:02:14 CEST | Business Wire | Press release
Supima presents the 3rd annual Supima Design Lab in its very first all-digital format, which will take place on Thursday, October 8th and be streamed live on Supima’s Instagram along with Fashion Network. Once again Supima brings together a select group of up and coming and leading designers from around the world. This year’s Supima Design Lab will showcase exclusive collections designed using American-grown Supima cotton featuring designs by the winner and finalists of the 2020 Supima Design Competition, the selection of the 2020 Hyères Fashion & Photography Festival and by leading International designers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005256/en/
Created exclusively for the Supima Design Lab, each design showcases the endless possibilities of fabrics made with Supima cotton. Stemming from a commitment to design, sustainable innovation and superior quality, Supima is unwavering in its ongoing programs that create platforms for designers to express themselves despite the challenges of Covid-19.
This Year’s Digital Runway show will be presenting “Made with Supima” Exclusive Designs by;
The Winner and Finalists of the 13th Annual Supima Design Competition
Amanda Forastieri, Drexel University – This Year’s Winner
Sakura Mizutani , Fashion Institute of Design & Merchandising
Jenny Feng , Fashion Institute of Technology
Jennie Nguyen , Kent State University
Terrence Zhou , Parsons School of Design
Kyra Buenviaje , Rhode Island School of Design
Finalists of 35th International Festival of Fashion, Fashion Photography and Accessories of Hyères
Katarzyna Agnieszka (France) Andrea Grossi (Italy)
Aline Boubert (France) Marvin M’Toumo (France)
Xavier Brisoux (France) Maximilian Rittler (Belgium)
Emma Bruschi (France) Céline Shen (France)
Timour Desdemoustier (Belgium) Tom van der Borght (Belgium)
Selected Leading Designers
Thierry Colson
Lutz Huelle
Dice Kayek
Jean Paul Knott
On Aura Tout Vu
As a special addition to this year’s Supima Design Lab, there will be a round table orchestrated by Benjamin Simmenauer, Permanent Professor at Institut Français de la Mode, Fashion Expert & Brand Strategist. The round table includes a select panel of industry leaders for an in-depth discussion of the Supima Design Lab - From the Fields to the Runway. This year’s panelists include :
Jean-Pierre Blanc , Founder, International Festival of Fashion, Photography and Accessories of Hyères
Godfrey Deeny , International Editor-in-Chief, FashionNetwork
Marc Lewkowitz , President & CEO, Supima
Buxton Midyette , VP Marketing & Promotions, Supima
« We are truly honored to continue working with our SDC Partner School finalists, the selection from the Festival de Hyères and our Leading Designer group. During the pandemic, we knew it was more important than ever to stay nimble and shift the Supima Design Lab into a virtual format to support these emerging designers achieve success in the fashion industry »
Buxton Midyette, VP Marketing & Promotions, Supima
About Supima :
Supima is America’s premium cotton. Founded in 1954, the Supima brand, short for « Superior Pima », designates an elite variety of pima cotton sustainably grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color and indulgent softness.
Follow Us on Social:
Instagram: @Supima
Facebook: @Supima
Twitter: @Supima
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005256/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom